The OnePlus Nord and several other OnePlus devices have had the glory of flaunting an AMOLED panel, but have so far missed out on one crucial feature of AMOLED displays - the ability to provide important information on the lockscreen using an always-on display.
We all know that the pre-order time of OnePlus Nord has already started via Amazon and this is one of the cheapest 5G smartphones in the Indian market. The OnePlus 8T series is said to be launching later this year and we can expect it to be a pioneer for AOD.
An OnePlus handset with model number KB2001 has recently appeared on the GeekBench benchmark website and while the site doesn't explicitly mention OnePlus 8T, it's widely believed that the handset is either OnePlus 8T or the 8T Pro. Severe color distortion is observed at the display brightness below 25%. It could be a possibility that OnePlus launches this device with the same processor, considering it will be a flagship offering. But this screen tinting issue on OnePlus Nord can be solved through software patch we are not sure. As you can see on the picture green tint is really present on the right of the screen compared to the OP 8 Pro. Hope this will be fixed soon! "I'm a little anxious", wrote a user in the official OnePlus forum. There is no official response by the company on this display issue.
The fact is that the screen is not the only front that has emerged for the OnePlus Nord in its few weeks on sale. OnePlus will continue to look into cutting-edge display technologies and strive to deliver the best user experience possible.
Apple Q3 2020 Results - $59.7 Billion Revenue
But the region returned to growth in the June quarter and registered $9.3 billion in revenue, up 2% year over year. The company said it has more than 550 million paid subscriptions and is on track to reach 600 million by year-end.
J&J Covid-19 vaccine protected monkey in single shot
The trial began at Rana Hospital and Trauma Centre, which is among the 12 institutes selected for clinical trials of the vaccine. Pending clinical trial outcomes, the vaccine is on track to start a phase 3 efficacy trial in 30,000 participants in September.